We are analyzing https://link.springer.com/article/10.1007/bf00874441.

Title:
Efficacy of prednisone in refractory multiple myeloma and measurement of glucocorticoid receptors | Investigational New Drugs
Description:
Background: Prednisone is an active drug in the treatment of multiple myeloma. The optimal dose, frequency, and role of glucocorticoid receptors (GR) in response to prednisone is unknown.Purpose: The purposes of this study were (1) to estimate the response rate of alternate-day high dose prednisone in patients with relapsing and refractory multiple myeloma; (2) to measure the range of GR levels; and (3) to correlate the response of prednisone with GR status.Patients and methods: Between 8/86 and 1/90, 127 patients were entered onto the study with 121 evaluable for response. The number of GR sites/cell was determined on mononuclear cells isolated from pretreatment bone marrow aspirates using a one point GR binding assay. Patients received prednisone 100 mg po qod x 2 weeks, followed by 50 mg po qod x 10 weeks.Results: The overall response rate was 10% (95% CI: 5–15%) with a median survival of 11.8 months. The GR sites/cell ranged from 0–53,212 with a mean of 8,371 sites/cells. Stratification of GR sites into 0–2,500, 2,501–6,000 and > 6,000 sites/cells was associated with a response rate of 6%, 27% and 4% respectively (p = 0.009). The median survival of patients in these categories was 8.1, 14.9 and 10.6 months respectively. This was not significant by the logrank test (p = 0.11). Although myeloma patients with intermediate levels of GR sites/cell initially responded more favorably to prednisone, their long-term survival was not significantly improved.Conclusions: Alternate-day high-dose prednisone was well tolerated and may provide palliative benefit for a subset of patients with relapsing and refractory multiple myeloma. The survival of patients on this study was comparable to that reported with other but more toxic doses of glucocorticoids.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Non-Profit & Charity

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

google, scholar, myeloma, glucocorticoid, multiple, prednisone, cancer, receptors, article, human, response, patients, thompson, cells, res, receptor, refractory, survival, leukemia, privacy, cookies, content, access, blood, data, publish, search, study, phase, dose, rate, levels, binding, highdose, resistance, acute, vitro, cell, dexamethasone, interleukin, information, log, journal, research, drugs, gupta, stocknovack, salmon, bonnet, treatment,

Topics {✒️}

alternate-day high-dose prednisone month download article/chapter intermittent high-dose predisone high dose chemotherapy gr sites/cell ranged single-agent steroid trial donna stock-novack vitro glucocorticoid studies high-dose glucocorticoid treatment related subjects arizona cancer center steroid hormone resistance privacy choices/manage cookies alpha omega publishing statistical methods based refractory multiple myeloma human multiple myelomas aggressive multiple myeloma thein vitro responses full article pdf cell cycle position high-dose dexamethasone gr sites/cell single point mutation leukaemic human leukocytes distinct receptor phenotypes isolated human leukemia long-term survival acute lymphoblastic leukemia phase ib trial dose intensity analysis european economic area mononuclear cells isolated provide palliative benefit leukemic sezary cells myelomonocytic leukemic cells seventh tenovus workshop exact significance levels cornwell iii gg zinc finger mutations alter domain interaction o'malley bw constitutive transcriptional activity texas medical branch relapsing multiple myeloma acute myelogenous leukemia conditions privacy policy glucocorticoid binding proteins detera-wadleigh sd brad thompson

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Efficacy of prednisone in refractory multiple myeloma and measurement of glucocorticoid receptors
         description: Background: Prednisone is an active drug in the treatment of multiple myeloma. The optimal dose, frequency, and role of glucocorticoid receptors (GR) in response to prednisone is unknown.Purpose: The purposes of this study were (1) to estimate the response rate of alternate-day high dose prednisone in patients with relapsing and refractory multiple myeloma; (2) to measure the range of GR levels; and (3) to correlate the response of prednisone with GR status.Patients and methods: Between 8/86 and 1/90, 127 patients were entered onto the study with 121 evaluable for response. The number of GR sites/cell was determined on mononuclear cells isolated from pretreatment bone marrow aspirates using a one point GR binding assay. Patients received prednisone 100 mg po qod x 2 weeks, followed by 50 mg po qod x 10 weeks.Results: The overall response rate was 10% (95% CI: 5–15%) with a median survival of 11.8 months. The GR sites/cell ranged from 0–53,212 with a mean of 8,371 sites/cells. Stratification of GR sites into 0–2,500, 2,501–6,000 and > 6,000 sites/cells was associated with a response rate of 6%, 27% and 4% respectively (p = 0.009). The median survival of patients in these categories was 8.1, 14.9 and 10.6 months respectively. This was not significant by the logrank test (p = 0.11). Although myeloma patients with intermediate levels of GR sites/cell initially responded more favorably to prednisone, their long-term survival was not significantly improved.Conclusions: Alternate-day high-dose prednisone was well tolerated and may provide palliative benefit for a subset of patients with relapsing and refractory multiple myeloma. The survival of patients on this study was comparable to that reported with other but more toxic doses of glucocorticoids.
         datePublished:
         dateModified:
         pageStart:121
         pageEnd:128
         sameAs:https://doi.org/10.1007/BF00874441
         keywords:
            multiple myeloma
            glucocorticoid receptors
            prednisone
            Oncology
            Pharmacology/Toxicology
         image:
         isPartOf:
            name:Investigational New Drugs
            issn:
               1573-0646
               0167-6997
            volumeNumber:12
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Kluwer Academic Publishers
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Vicram Gupta
               affiliation:
                     name:University of Texas Medical Branch
                     address:
                        name:University of Texas Medical Branch, Galveston
                        type:PostalAddress
                     type:Organization
               type:Person
               name:E. Brad Thompson
               affiliation:
                     name:University of Texas Medical Branch
                     address:
                        name:University of Texas Medical Branch, Galveston
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Donna Stock-Novack
               affiliation:
                     name:Southwest Oncology Group Statistical Center
                     address:
                        name:Southwest Oncology Group Statistical Center, Seattle
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sydney E. Salmon
               affiliation:
                     name:University of Arizona Cancer Center
                     address:
                        name:University of Arizona Cancer Center, Tucson
                        type:PostalAddress
                     type:Organization
               type:Person
               name:H. Irving Pierce
               affiliation:
                     name:Northwest CCOP
                     address:
                        name:Northwest CCOP, Tacoma
                        type:PostalAddress
                     type:Organization
               type:Person
               name:John D. Bonnet
               affiliation:
                     name:Scott & White Clinic
                     address:
                        name:Scott & White Clinic, Temple, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:David Chilton
               affiliation:
                     name:University of Texas Medical Branch
                     address:
                        name:University of Texas Medical Branch, Galveston
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jean Beckord
               affiliation:
                     name:Southwest Oncology Group Statistical Center
                     address:
                        name:Southwest Oncology Group Statistical Center, Seattle
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Efficacy of prednisone in refractory multiple myeloma and measurement of glucocorticoid receptors
      description: Background: Prednisone is an active drug in the treatment of multiple myeloma. The optimal dose, frequency, and role of glucocorticoid receptors (GR) in response to prednisone is unknown.Purpose: The purposes of this study were (1) to estimate the response rate of alternate-day high dose prednisone in patients with relapsing and refractory multiple myeloma; (2) to measure the range of GR levels; and (3) to correlate the response of prednisone with GR status.Patients and methods: Between 8/86 and 1/90, 127 patients were entered onto the study with 121 evaluable for response. The number of GR sites/cell was determined on mononuclear cells isolated from pretreatment bone marrow aspirates using a one point GR binding assay. Patients received prednisone 100 mg po qod x 2 weeks, followed by 50 mg po qod x 10 weeks.Results: The overall response rate was 10% (95% CI: 5–15%) with a median survival of 11.8 months. The GR sites/cell ranged from 0–53,212 with a mean of 8,371 sites/cells. Stratification of GR sites into 0–2,500, 2,501–6,000 and > 6,000 sites/cells was associated with a response rate of 6%, 27% and 4% respectively (p = 0.009). The median survival of patients in these categories was 8.1, 14.9 and 10.6 months respectively. This was not significant by the logrank test (p = 0.11). Although myeloma patients with intermediate levels of GR sites/cell initially responded more favorably to prednisone, their long-term survival was not significantly improved.Conclusions: Alternate-day high-dose prednisone was well tolerated and may provide palliative benefit for a subset of patients with relapsing and refractory multiple myeloma. The survival of patients on this study was comparable to that reported with other but more toxic doses of glucocorticoids.
      datePublished:
      dateModified:
      pageStart:121
      pageEnd:128
      sameAs:https://doi.org/10.1007/BF00874441
      keywords:
         multiple myeloma
         glucocorticoid receptors
         prednisone
         Oncology
         Pharmacology/Toxicology
      image:
      isPartOf:
         name:Investigational New Drugs
         issn:
            1573-0646
            0167-6997
         volumeNumber:12
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Kluwer Academic Publishers
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Vicram Gupta
            affiliation:
                  name:University of Texas Medical Branch
                  address:
                     name:University of Texas Medical Branch, Galveston
                     type:PostalAddress
                  type:Organization
            type:Person
            name:E. Brad Thompson
            affiliation:
                  name:University of Texas Medical Branch
                  address:
                     name:University of Texas Medical Branch, Galveston
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Donna Stock-Novack
            affiliation:
                  name:Southwest Oncology Group Statistical Center
                  address:
                     name:Southwest Oncology Group Statistical Center, Seattle
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sydney E. Salmon
            affiliation:
                  name:University of Arizona Cancer Center
                  address:
                     name:University of Arizona Cancer Center, Tucson
                     type:PostalAddress
                  type:Organization
            type:Person
            name:H. Irving Pierce
            affiliation:
                  name:Northwest CCOP
                  address:
                     name:Northwest CCOP, Tacoma
                     type:PostalAddress
                  type:Organization
            type:Person
            name:John D. Bonnet
            affiliation:
                  name:Scott & White Clinic
                  address:
                     name:Scott & White Clinic, Temple, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:David Chilton
            affiliation:
                  name:University of Texas Medical Branch
                  address:
                     name:University of Texas Medical Branch, Galveston
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jean Beckord
            affiliation:
                  name:Southwest Oncology Group Statistical Center
                  address:
                     name:Southwest Oncology Group Statistical Center, Seattle
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Investigational New Drugs
      issn:
         1573-0646
         0167-6997
      volumeNumber:12
Organization:
      name:Kluwer Academic Publishers
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Texas Medical Branch
      address:
         name:University of Texas Medical Branch, Galveston
         type:PostalAddress
      name:University of Texas Medical Branch
      address:
         name:University of Texas Medical Branch, Galveston
         type:PostalAddress
      name:Southwest Oncology Group Statistical Center
      address:
         name:Southwest Oncology Group Statistical Center, Seattle
         type:PostalAddress
      name:University of Arizona Cancer Center
      address:
         name:University of Arizona Cancer Center, Tucson
         type:PostalAddress
      name:Northwest CCOP
      address:
         name:Northwest CCOP, Tacoma
         type:PostalAddress
      name:Scott & White Clinic
      address:
         name:Scott & White Clinic, Temple, USA
         type:PostalAddress
      name:University of Texas Medical Branch
      address:
         name:University of Texas Medical Branch, Galveston
         type:PostalAddress
      name:Southwest Oncology Group Statistical Center
      address:
         name:Southwest Oncology Group Statistical Center, Seattle
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Vicram Gupta
      affiliation:
            name:University of Texas Medical Branch
            address:
               name:University of Texas Medical Branch, Galveston
               type:PostalAddress
            type:Organization
      name:E. Brad Thompson
      affiliation:
            name:University of Texas Medical Branch
            address:
               name:University of Texas Medical Branch, Galveston
               type:PostalAddress
            type:Organization
      name:Donna Stock-Novack
      affiliation:
            name:Southwest Oncology Group Statistical Center
            address:
               name:Southwest Oncology Group Statistical Center, Seattle
               type:PostalAddress
            type:Organization
      name:Sydney E. Salmon
      affiliation:
            name:University of Arizona Cancer Center
            address:
               name:University of Arizona Cancer Center, Tucson
               type:PostalAddress
            type:Organization
      name:H. Irving Pierce
      affiliation:
            name:Northwest CCOP
            address:
               name:Northwest CCOP, Tacoma
               type:PostalAddress
            type:Organization
      name:John D. Bonnet
      affiliation:
            name:Scott & White Clinic
            address:
               name:Scott & White Clinic, Temple, USA
               type:PostalAddress
            type:Organization
      name:David Chilton
      affiliation:
            name:University of Texas Medical Branch
            address:
               name:University of Texas Medical Branch, Galveston
               type:PostalAddress
            type:Organization
      name:Jean Beckord
      affiliation:
            name:Southwest Oncology Group Statistical Center
            address:
               name:Southwest Oncology Group Statistical Center, Seattle
               type:PostalAddress
            type:Organization
PostalAddress:
      name:University of Texas Medical Branch, Galveston
      name:University of Texas Medical Branch, Galveston
      name:Southwest Oncology Group Statistical Center, Seattle
      name:University of Arizona Cancer Center, Tucson
      name:Northwest CCOP, Tacoma
      name:Scott & White Clinic, Temple, USA
      name:University of Texas Medical Branch, Galveston
      name:Southwest Oncology Group Statistical Center, Seattle
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(76)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.29s.

LINK . SPRINGER . COM {}